Monica Ter-Minassian, ScD

MTM2017

Research Scientist

301-816-5682
Monica.Ter-Minassian@kp.org

Education:

ScD in Environmental and Occupational Epidemiology, Harvard School of Public Health, 2009
MS in Epidemiology, Harvard School of Public Health, 2006
MS in Cell and Molecular Biology, Genetic Counseling Program, Brandeis University, 1999

Professional Affiliations:

American Society of Clinical Oncology
American Association of Cancer Research
International Society of Pharmacoepidemiology
North American Neuroendocrine Tumor Society

 

Dr. Monica Ter-Minassian is a Research Scientist at the Mid-Atlantic Permanente Research Institute (MAPRI) who joined the team in January 2016. Her research focuses on oncology epidemiology and she furthers the development and curation of a SEER-compliant Cancer Registry. She is responsible for developing and maintaining the KP Mid-Atlantic Sickle Cell Disease and Related Hemoglobinopathies Registry.

Prior to joining Kaiser Permanente, she was a joint Research Fellow at the Dana-Farber Cancer Institute and the Harvard School of Public Health where she studied heritable genetic variants associated with neuroendocrine tumor risk and non-small cell lung cancer risk. She also examined prognostic markers for patients with neuroendocrine tumors, particularly molecular markers associated with outcomes on targeted therapies.

Research Interests:

Cancer and oncology epidemiology, genetic and molecular epidemiology, sickle-cell disease

For a full list of publications, please see Dr. Ter-Minassian’s Curriculum Vitae.

  1. Ter-Minassian M, Zhang S, Brooks NV, Brais LK, Chan JA, Christiani DC, Lin X, Gabriel S, Dinet J, Kulke MH. Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors. Oncologist. 2017 Feb;22(2):165-172.
  2. Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, Masugi Y, Thiaglingam A, Brooks N, Nishihara R, Bonnemarie M, Masuda A, Inamura K, Kim SA, Mima K, Sukawa Y, Dou R, Lin X, Christiani DC, Schmidlin F, Fuchs CS, Mahmood U, Ogino S, Kulke MH. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas. 2016 Nov;45(10):1386-1393. PMCID: PMC5067972.
  3. Du Y, Ter-Minassian M, Brais L, Brooks N, Waldron A, Chan JA, Lin X, Kraft P,Christiani DC, Kulke MH. Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study. Endocr Relat Cancer. 2016 Aug;23(8):587-94.
  4. Qian ZR, Ter-Minassian M, Chan JA, Imamura Y, Hooshmand SM, Kuchiba A, Morikawa T, Brais LK, Daskalova A, Heafield R, Lin X, Christiani DC, Fuchs CS, Ogino S, Kulke MH. Prognostic significance of MTOR pathway component expression in neuroendocrine tumors. J Clin Oncol. 2013 Sep 20;31(27):3418-25.
  5. Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, Buchanan L, Qian ZR, Fuchs CS, Lin X, Liu G, Christiani DC, Kulke MH. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocrine Related Cancer. 2013. 22;20(2):187-96.
  6. Zhao Y, Yu H, Zhu Y, Ter-Minassian M, Peng Z, Shen H, Diao N, Chen F. Genetic association analysis using sibship data: a multilevel model approach. PLoS One. 2012;7(2):e31134.
  7. Zhai R, Zhao Y, Liu G, Ter-Minassian M, Wu IC, Wang Z, Su L, Asomaning K, Chen F, Kulke MH, Lin X, Heist RS, Wain JC, Christiani DC. Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: a case-only study. Cancer. 2012 Feb1;118(3):804-11.
  8. Ter-Minassian M, Wang Z, Asomaning K, Wu MC, Liu CY, Paulus JK, Liu G, Bradbury PA, Zhai R, Su L, Frauenhoffer CS, Hooshmand SM, De Vivo I, Lin X, Christiani DC, Kulke MH. Genetic associations with sporadic neuroendocrine tumor risk. Carcinogenesis. 2011 Aug;32(8):1216-22.
  9. Ter-Minassian M, Asomaning K, Zhao Y, Chen F, Su L, Carmella SG, Lin X, Hecht SS, Christiani DC. Genetic variability in the metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). Int J Cancer. 2011 Mar 15;130(6):1338-46.
  10. Wu IC, Zhao Y, Zhai R, Liu G, Ter-Minassian M, Asomaning K, Su L, Liu CY, Chen F, Kulke MH, Heist RS, Christiani DC. Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma. Neoplasia. 2011 Apr;13(4):386-92.
  1. Sentinel Initiative Operations Center Data Partner
    Funder: Federal Drug Administration/Harvard Pilgrim Health Care
    Role: Site Principal Investigator
  2. Sentinel Task order: COPD, Asthma, And Respiratory Disease Effectiveness (CARE) For 21st Century Cures
    Funder
    : Federal Drug Administration/Harvard Pilgrim Health Care
    Role: Site Principal Investigator
  3. Benign Breast Disease: Cohort identification for Breast Cancer Screening and Pathology Analysis
    Funder
    : Johns Hopkins/KPMAS Collaboration
    Role: Site Principal Investigator
  4. Preventative Strategies for Patients at High Risk for Breast cancer
    Funder:
    Kaiser Permanente Community Benefit
    Role:
    Principal Investigator
  5. KPRB Cancer Cohort
    Funder:
    KP Research Bank
    Role:
    Co-Investigator
  6. Sickle Cell Disease Quality Measures and Outcomes
    Funder:
    Kaiser Permanente Community Benefit
    Role:
    Co-Investigator
  1. Oral Presentation: Large-scale SNP Evaluation Reveals an Association of a TSC2 SNP with Sporadic Neuroendocrine Tumor Risk. The North American Neuroendocrine Tumor Society symposium, Charlotte, NC, 2009. Supported by NANETS travel grant.